Factor VIII polymer conjugates
View Patent ↗The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.
1. A method of administering a composition in an amount effective to treat a bleeding disorder to a subject in need thereof, comprising:
i) determining a dosage amount for a subject suffering from a bleeding disorder based on type of bleeding disorder, severity of the bleeding disorder, and the subject's clinical history; and
ii) administering a composition comprising (i) (a) a Factor VIII molecule; and (b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via one or more carbohydrate moieties located in the B domain of Factor VIII, wherein said molecule retains at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient.
2. The method of claim 1 , wherein said composition is substantially free from albumin.
3. The method of claim 1 , wherein said water soluble polymer is attached to said carbohydrate moiety via a linker.
4. The method of claim 3 , wherein said linker is 4-[4-N-maleimidophenyl]butyric acid hydrazide (MBPH).
5. The method of claim 3 , wherein the linker is releasable or hydrolysable.
6. The method of claim 1 , wherein said water soluble polymer is selected from the group consisting of polyethylene glycol (PEG), polysialic acid (PSA) and dextran.
7. The method according to claim 1 , wherein said modified Factor VIII retains at least 60% of native FVIII activity.
8. The method according to claim 7 , wherein said modified Factor VIII retains at least 70% of native FVIII activity.
9. The method according to claim 1 , wherein said bleeding disorder is hemophilia A.
10. The method of claim 1 , wherein said water soluble polymer has a molecular weight of 2,000 to 150,000 Da.
11. The method of claim 10 , wherein said water soluble polymer has a molecular weight of 5,000 to 50,000 Da.
12. The method of claim 1 , wherein said water soluble polymer is branched.
13. The method of claim 1 , wherein said water soluble polymer is linear.
14. The method of claim 1 , wherein the Factor VIII is recombinant Factor VIII.
15. The method of claim 1 , wherein the Factor VIII is plasmatic Factor VIII.
16. The method of claim 1 , wherein the composition comprises a plurality of conjugates, each having at least one water soluble polymer bound to a native Factor VIII, said water soluble polymer attached to the modified Factor VIII via one or more carbohydrate moieties, said modified Factor VIII retaining at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient.
17. The method of claim 1 , wherein the composition further comprises an unconjugated Factor VIII moiety.
18. A kit comprising a pharmaceutical composition comprising (i) (a) a Factor VIII molecule; and (b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via one or more carbohydrate moieties located in the B domain of Factor VIII, wherein said molecule retains at least 50% of native FVIII activity, and (ii) a pharmaceutically acceptable excipient; packaged in a container with a label that describes use of the pharmaceutical composition in the method of claim 1 .
19. A kit according to claim 18 , wherein the pharmaceutical composition is packaged in a unit dose form.
20. A kit comprising a first container comprising (a) a Factor VIII molecule; and (b) at least one water soluble polymer bound to said Factor VIII molecule, wherein said water soluble polymer is attached to the Factor VIII via one or more carbohydrate moieties located in the B domain of Factor VIII, wherein said molecule retains at least 50% of native FVIII activity, and a second container comprising a physiologically acceptable reconstitution solution for said conjugate in the first container, wherein said kit is packaged with a label that describes use of the pharmaceutical composition in the method of claim 1 .
21. A kit according to claim 20 , wherein the pharmaceutical composition is packaged in a unit dose form.